DDO-4033
DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM) . DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research[1].
Product Specifications
UNSPSC
12352005
Target
E1/E2/E3 Enzyme; YAP
Related Pathways
Metabolic Enzyme/Protease; Stem Cell/Wnt
Field of Research
Cancer
Smiles
C#CC1=C([N+]([O-])=O)C=C(C(NC2=CC(C)=NN2C(N3)=NC(CCC)=CC3=O)=O)C=C1
Molecular Formula
C20H18N6O4
Molecular Weight
406.39
References & Citations
[1]Zhang Q, et al. Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy. J Med Chem. 2025 Jul 24;68 (14) :14945-14961.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
E3225-01C-ML650 100 µL
ENT1, phosphorylated (Ser254) (Equilibrative Nitrobenzylmercaptopurine Riboside-sensitive Nucleoside Transporter, Equilibrative NBMPR-sensitive Nucleoside Transporter, Nucleoside Transporter, es-type, Solute Carrier Family 29 Member 1, Slc29a1, Equilibrative Nucleoside Transporter 1) (MaxLight 650) discontinued
Ask
View Details PDC-OPD 1 Unit
Dry Oxygen Service Pump, 115V (includes adaptor, centering ring, connectors and hose; no fluid required)
Ask
View Details